Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Daiwa America

Daiwa America upgraded shares of Gilead Sciences (NASDAQ:GILD) to a hold rating in a report published on Monday morning,Zacks.com reports.

Several other brokerages also recently issued reports on GILD. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. BMO Capital Markets raised their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Barclays boosted their price objective on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Finally, Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $94.00.

Gilead Sciences Price Performance

Shares of GILD opened at $88.63 on Monday. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $110.46 billion, a price-to-earnings ratio of 984.78, a PEG ratio of 2.72 and a beta of 0.17. The stock has a 50 day moving average of $87.15 and a 200-day moving average of $76.52.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.29 earnings per share. As a group, analysts forecast that Gilead Sciences will post 4.38 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.48%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in GILD. Westside Investment Management Inc. raised its position in Gilead Sciences by 3.5% in the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock worth $2,249,000 after purchasing an additional 917 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in Gilead Sciences by 3.6% in the third quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 333 shares during the last quarter. TD Private Client Wealth LLC increased its position in Gilead Sciences by 10.6% in the third quarter. TD Private Client Wealth LLC now owns 57,509 shares of the biopharmaceutical company’s stock worth $4,822,000 after purchasing an additional 5,497 shares during the period. TT International Asset Management LTD acquired a new position in Gilead Sciences during the 3rd quarter valued at about $1,257,000. Finally, Coldstream Capital Management Inc. boosted its stake in shares of Gilead Sciences by 9.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company’s stock valued at $1,932,000 after purchasing an additional 2,043 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.